Aa
A
A
A
Close
Cirrhosis of the Liver Community
731 Members
Avatar universal

New drug claimed to reverse fibrosis and cirrhosis.

I don't remember seeing anything on MedHelp about this Company/drug which is now in phase II trials. It claims to reverse fibrosis and cirrhosis in NASH and NAFDL but I see no reason why it wouldn't be beneficial in HCV and HBV patients as well as liver diseases in general. I've been watching Galectin since June 2013.
Sept. 10, 2013, 8:00 a.m. EDT
Galectin Therapeutics Receives US Patent for Potential Ground-Breaking Treatment for Fatty Liver Disease

NORCROSS, Ga., Sep 10, 2013 (GLOBE NEWSWIRE via COMTEX) -- Galectin Therapeutics GALT +4.37% , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of issuance from the U.S. Patent and Trademark Office for Patent Application Number 13/573,454 titled "Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease." The patent covers the Company's carbohydrate-based galectin inhibitor compound GR-MD-02 for use in patients with fatty liver disease with or without fibrosis or cirrhosis. Fatty liver disease affects as many as 15 million Americans, results in severe scarring of the liver (cirrhosis), and there are no currently approved pharmaceutical therapies.

The U.S. Food and Drug Administration (FDA) recently granted GR-MD-02 Fast Track designation for non-alcoholic steatohepatitis (NASH) with hepatic fibrosis, commonly known as fatty liver disease with advanced fibrosis. Galectin Therapeutics is currently conducting a Phase 1 clinical trial to evaluate the safety, tolerability and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 over four weekly doses of GR-MD-02 treatment in patients with fatty liver disease with advanced fibrosis.

"The issuance of this patent provides broad coverage in the U.S. for the use of GR-MD-02 in fatty liver disease through September 2031 and international patent coverage is pending for the same intellectual property," said Peter G. Traber, MD, President, CEO and CMO of Galectin Therapeutics. "There is a truly vast unmet medical need for the treatment of fatty liver disease with fibrosis, as the most prevalent liver disease in the U.S. We are hopeful that our development program for GR-MD-02 will lead to the first therapy for this unmet medical need."

The patent inventors include Peter Traber, Eliezer Zomer and Anatole Klyosov with assignment to Galectin Therapeutics. The major claims are for methods of obtaining galectin inhibitor compounds, obtaining a composition for parenteral or enteral administration in an acceptable pharmaceutical carrier and administering to a subject having at least one of the following: fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, non-alcoholic hepatitis with liver fibrosis, non-alcoholic steatohepatitis with cirrhosis, or non-alcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma. The use covers reversing or slowing the progression of disease activity or medical consequences of the disease. Moreover, additional claims cover the use of the galectin inhibitor compounds in combination with multiple other agents that may have potential activity in the disease that are under investigation elsewhere.

About Fatty Liver Disease with Advanced Fibrosis

Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease, has become a common disease of the liver with the rise in obesity rates, estimated to affect nine to 15 million people, including children, in the U.S. Fatty liver disease is characterized by the presence of fat in the liver along with inflammation and damage in people who drink little or no alcohol. Over time, patients with fatty liver disease can develop fibrosis, or scarring of the liver, and it is estimated that as many as three million individuals will develop cirrhosis, a severe liver disease where liver transplantation is the only current treatment available. Approximately 6,300 liver transplants are done on an annual basis in the U.S. There are no drug therapies approved for the treatment of liver fibrosis. FDA and AASLD (American Association for the Study of Liver Disease) recently held a 2-day workshop with leading scientific experts in NASH and key FDA officials to discuss acceptable regulatory endpoints for approval of drugs to treat NASH (http://www.aasld.org/additionalmeetings/Pages/aasldfdanash.aspx).

About Galectin Therapeutics

Galectin Therapeutics GALT +4.37% is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

http://www.marketwatch.com/story/galectin-therapeutics-receives-us-patent-for-potential-ground-breaking-treatment-for-fatty-liver-disease-2013-09-10
3 Responses
Avatar universal
MEDICAL PROFESSIONAL
Hi, thanks for sharing. Galectins are a family of beta-galactoside-binding animal lectins. It is expressed in various tissues and organs but is significantly absent in normal hepatocytes. But galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. So, based on presently known properties of this lectin, it is possible that deregulated expression of galectin-3 can result in tumor transformation and invasiveness. Studies and clinical trials are being conducted to achieve this. Regards.
317787 tn?1473358451
Hi Mike, really interesting, odd thing, I thought I responded to this when you posted it, This sounds really good, I am going to follow this

I have recently started waking at 3 am every morning.  I am not sure what is going on.  I read an article that said our liver does it's cleansing in 1 to 3.

As as aside I read that our liver does not nourish our tendons well due to damage, have you heard anything about this?
317787 tn?1473358451
Dejavu? Hah I did read this before, it was in the HCV thread, really nice of you to post it over here for others to read
I just had to come back and say I am not crazy, I did see it before :)

While I am here again with the Deja Vu and 3AM can I ask why I am waking at 3AM?
I think it has something to do with the liver, I am hoping it is not HE

Of course then I could blame any odd behavior on that.  Maybe I will slink off and find a trial that you mentioned, I am sure that would help.
Have an Answer?
Top Hepatitis Answerers
317787 tn?1473358451
DC
683231 tn?1467323017
Auburn, WA
Avatar universal
Ro, Romania
Learn About Top Answerers
Didn't find the answer you were looking for?
Ask a question
Popular Resources
For people with Obsessive-Compulsive Disorder (OCD), the COVID-19 pandemic can be particularly challenging.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Here’s how your baby’s growing in your body each week.
These common ADD/ADHD myths could already be hurting your child
This article will tell you more about strength training at home, giving you some options that require little to no equipment.
In You Can Prevent a Stroke, Dr. Joshua Yamamoto and Dr. Kristin Thomas help us understand what we can do to prevent a stroke.